- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Immunovant (IMVT)
Company Profile
| Quarter (USD) | Dec 25 | Sep 25 | Jun 25 | Mar 25 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 994.53 mm | 994.53 mm | 994.53 mm | 994.53 mm | 994.53 mm | 994.53 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 36.36 mm | 38.38 mm | 30.78 mm | 35.24 mm |
| Cash used (since last report) | n/a | n/a | 46.17 mm | 48.73 mm | 39.07 mm | 44.74 mm |
| Cash remaining | n/a | n/a | 948.36 mm | 945.80 mm | 955.45 mm | 949.78 mm |
| Runway (months of cash) | n/a | n/a | 26.1 | 24.6 | 31.0 | 27.0 |
| 13F holders | Current |
|---|---|
| Total holders | 189 |
| Opened positions | 39 |
| Closed positions | 36 |
| Increased positions | 67 |
| Reduced positions | 60 |
| 13F shares | Current |
|---|---|
| Total value | 1.82 tn |
| Total shares | 159.95 mm |
| Total puts | 561.20 k |
| Total calls | 2.47 mm |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| ROIV Roivant Sciences | 79.82 mm | $2.76 bn |
| FMR | 13.10 mm | $324.44 bn |
| Vanguard | 6.68 mm | $165.45 bn |
| Deep Track Capital | 6.00 mm | $148.62 bn |
| BLK BlackRock | 5.14 mm | $127.39 bn |
| T. Rowe Price Investment Management | 5.12 mm | $126.75 mm |
| Armistice Capital | 3.87 mm | $95.87 bn |
| STT State Street | 2.70 mm | $66.82 bn |
| Alpine Global Management | 2.16 mm | $53.48 bn |
| Perceptive Advisors | 2.14 mm | $52.99 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Jan 26 | Jay S Stout | Common Stock | Sell | Dispose S | No | No | 26.03 | 1,977 | 51.46 k | 197,634 |
| 7 Jan 26 | Jay S Stout | Common Stock | Sell | Dispose S | No | No | 26.92 | 55 | 1.48 k | 199,611 |
| 7 Jan 26 | Jay S Stout | Common Stock | Sell | Dispose S | No | No | 26.51 | 1,148 | 30.43 k | 199,666 |
| 18 Dec 25 | Tuyl Christopher Van | Common Stock | Sell | Dispose S | No | No | 27.38 | 2,284 | 62.54 k | 149,930 |
| 18 Dec 25 | Tuyl Christopher Van | Common Stock | Sell | Dispose S | No | No | 26.78 | 8,529 | 228.41 k | 152,214 |
| 12 Dec 25 | Roivant Sciences | Common Stock, $0.0001 par value per share | Buy | Acquire P | No | No | 21 | 16,666,666 | 350.00 mm | 113,317,007 |
| 1 Dec 25 | Hughes Douglas J. | Common Stock | Sell | Dispose S | No | Yes | 23.96 | 1,909 | 45.74 k | 120,773 |
| 1 Dec 25 | Hughes Douglas J. | Common Stock | Sell | Dispose S | No | Yes | 23.14 | 13,091 | 302.93 k | 122,682 |